Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 13/20 | 0.95 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | KDM1A | O60341 | 4/20 | 0.67 |
| ▸ | PDE5A | O76074 | 2/20 | 0.67 |
| ▸ | GBA1 | P04062 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8087337 | 0.95 | ABCG2 (0.85) | ABCG2MEN1KMT2ALMNATP53 | |
| SCHEMBL4085140 | 0.94 | ABCG2 (0.83) | ABCG2MEN1KMT2ALMNATP53 | |
| SCHEMBL13945462 | 0.92 | ABCG2 (0.80) | ABCG2MEN1KMT2ALMNATP53 | |
| SCHEMBL4095375 | 0.89 | ABCG2 (0.74) | ABCG2MEN1KMT2ALMNATP53 | |
| SCHEMBL4092319 | 0.88 | ABCG2 (0.74) | ABCG2LMNATP53MAPTKDM1A | |
| SCHEMBL4085190 | 0.88 | ABCG2 (0.74) | ABCG2MEN1KMT2ALMNATP53 | |
| SCHEMBL22201364 | 0.84 | ABCG2 (0.94) | ABCG2MEN1KMT2ALMNATP53 | |
| SCHEMBL4092363 | 0.83 | PDE5A (0.76) | ABCG2MEN1KMT2ALMNATP53 | |
| SCHEMBL4090985 | 0.83 | ABCG2 (0.71) | ABCG2MEN1KMT2ALMNATP53 | |
| SCHEMBL1063103 | 0.82 | ABCG2 (1.00) | ABCG2MEN1KMT2ALMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2009-08-20 | — | — | US | disclosed |
| WO-2008157500-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209536-A1 | AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE | CNR2, CNR1, GPR18 | ABCG2 3127/4885MEN1 718/4885KMT2A 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.